#1 Clinical Trials Search in Europe

Tanimilast

This article explores the use of Tanimilast, a novel drug being studied in clinical trials for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Tanimilast is being investigated as an add-on therapy to existing treatments, with the goal of improving symptoms and reducing exacerbations in patients with uncontrolled asthma or COPD with chronic bronchitis. The trials are examining the efficacy and safety of Tanimilast at different doses when added to standard inhaled therapies.

Table of Contents

What is Tanimilast?

Tanimilast, also known as CHF6001, is a new medication being developed for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD)[1]. It belongs to a class of drugs called phosphodiesterase-4 (PDE-4) inhibitors, which work by reducing inflammation in the airways[2].

How Does Tanimilast Work?

Tanimilast works by inhibiting the enzyme phosphodiesterase-4, which plays a role in inflammatory processes in the body. By blocking this enzyme, Tanimilast helps to reduce inflammation in the airways, making it easier for patients with asthma or COPD to breathe[2]. This mechanism of action is particularly beneficial for patients who have not achieved adequate control of their symptoms with other medications.

Conditions Treated by Tanimilast

Tanimilast is being studied for the treatment of two main respiratory conditions:

  • Asthma: Specifically for patients with uncontrolled asthma who are already on inhaled corticosteroid and long-acting beta2-agonist therapy[1].
  • Chronic Obstructive Pulmonary Disease (COPD): Particularly for patients with COPD and chronic bronchitis who are on triple therapy (inhaled corticosteroids, long-acting beta2-agonists, and long-acting muscarinic antagonists)[3].

How is Tanimilast Administered?

Tanimilast is administered as an inhalation powder using a device called NEXThaler®[2]. This dry powder inhaler allows patients to inhale the medication directly into their lungs. The dosage being studied varies depending on the condition and specific clinical trial, ranging from 1600 to 3200 micrograms total daily dose[1][3].

Clinical Trials and Efficacy

Several clinical trials are currently underway to evaluate the efficacy and safety of Tanimilast:

  • For asthma: A 52-week study is assessing the ability of Tanimilast to reduce the rate of asthma exacerbations in patients with uncontrolled asthma[1].
  • For COPD: Two 52-week studies are evaluating the efficacy of Tanimilast in reducing moderate and severe exacerbations in COPD patients with chronic bronchitis[2][3].

These trials are also looking at improvements in lung function, quality of life, and other clinical outcomes. The results of these studies will help determine how effective Tanimilast is in managing these respiratory conditions.

Safety and Side Effects

As Tanimilast is still in clinical trials, comprehensive safety data is not yet available. However, the ongoing studies are closely monitoring for any adverse events. Common side effects of PDE-4 inhibitors may include gastrointestinal issues, headache, and weight loss, but it’s important to note that the side effect profile of Tanimilast may differ[2].

Patients with a history of certain conditions, such as severe cardiovascular diseases, liver diseases, or cancer, may not be eligible for treatment with Tanimilast based on the exclusion criteria of the clinical trials[1].

Conclusion

Tanimilast represents a promising new treatment option for patients with asthma and COPD, particularly those who have not achieved adequate control with current therapies. As an inhaled PDE-4 inhibitor, it offers a novel approach to reducing airway inflammation. While the results of ongoing clinical trials are eagerly awaited, Tanimilast has the potential to improve the quality of life for many patients with chronic respiratory conditions.

Aspect Details
Drug Name Tanimilast (CHF6001)
Administration Dry Powder Inhaler (NEXThaler)
Conditions Studied Uncontrolled Asthma, COPD with Chronic Bronchitis
Trial Phases Phase II (Asthma), Phase III (COPD)
Treatment Duration 52 weeks
Primary Endpoints Reduction in exacerbation rates
Secondary Endpoints Lung function, quality of life, safety and tolerability
Dosages Studied 1600 μg and 3200 μg daily
Add-on Therapy To Inhaled corticosteroids, long-acting beta2-agonists, long-acting muscarinic antagonists

FAQ

  • What is Tanimilast? Tanimilast is an investigational drug being studied as a potential treatment for asthma and chronic obstructive pulmonary disease (COPD). It is taken by inhalation using a dry powder inhaler.
  • What conditions is Tanimilast being studied for? Tanimilast is being studied for uncontrolled asthma and COPD with chronic bronchitis. The clinical trials are evaluating its use as an add-on therapy to existing inhaled treatments.
  • How is Tanimilast administered? Tanimilast is administered as an inhalation powder using a device called NEXThaler. Patients inhale the medication directly into their lungs.
  • What are the main goals of the Tanimilast clinical trials? The main goals are to evaluate the efficacy and safety of Tanimilast in reducing asthma and COPD exacerbations, improving lung function, and enhancing quality of life when added to standard inhaled therapies.
  • Who is eligible to participate in these clinical trials? Eligibility varies, but generally includes adults with uncontrolled asthma or COPD with chronic bronchitis who are already on inhaled therapies. Specific lung function measurements and exacerbation history are also considered.

Ongoing Clinical Trials on Tanimilast

  • Study comparing absorption of inhaled Tanimilast (CHF 6001) in adolescent and adult asthma patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria

  • Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

    Not recruiting

    1 1
    Investigated drugs:
    Austria Bulgaria Czechia Germany Greece Hungary +6

  • Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

    Not recruiting

    1 1
    Investigated drugs:
    Austria Bulgaria Croatia Czechia Estonia Germany +8

  • Study on the Effectiveness and Safety of Tanimilast for Patients with Uncontrolled Asthma on Inhaled Corticosteroid and Long-Acting Beta2-Agonist Therapy

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Italy Latvia +4

Glossary

  • Asthma: A chronic lung condition that causes inflammation and narrowing of the airways, leading to breathing difficulties, wheezing, and coughing.
  • COPD (Chronic Obstructive Pulmonary Disease): A group of lung diseases, including chronic bronchitis and emphysema, that cause airflow blockage and breathing-related problems.
  • Chronic Bronchitis: A type of COPD characterized by inflammation of the bronchial tubes, leading to excessive mucus production and persistent cough.
  • Exacerbation: A worsening of symptoms in chronic diseases like asthma or COPD, often requiring additional treatment or hospitalization.
  • FEV1 (Forced Expiratory Volume in 1 second): A measure of how much air a person can exhale in one second, used to assess lung function.
  • FVC (Forced Vital Capacity): The total amount of air exhaled during a forced breath, another measure of lung function.
  • ICS (Inhaled Corticosteroids): A type of anti-inflammatory medication inhaled directly into the lungs to reduce airway inflammation in asthma and COPD.
  • LABA (Long-Acting Beta2-Agonist): A type of bronchodilator medication that helps keep airways open for an extended period.
  • LAMA (Long-Acting Muscarinic Antagonist): Another type of long-acting bronchodilator used in COPD treatment.
  • Triple Therapy: A combination treatment for COPD that includes an ICS, LABA, and LAMA.
  • NEXThaler: The specific dry powder inhaler device used to administer Tanimilast in the clinical trials.
  • ACQ-7 (Asthma Control Questionnaire): A standardized questionnaire used to assess asthma control in patients.
  • SGRQ (St. George's Respiratory Questionnaire): A questionnaire designed to measure health-related quality of life in patients with respiratory diseases.
  • CAT (COPD Assessment Test): A questionnaire used to measure the impact of COPD on a person's life.
  • Pack-year: A measure of smoking history, calculated by multiplying the number of packs of cigarettes smoked per day by the number of years a person has smoked.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tanimilast-for-patients-with-uncontrolled-asthma-on-inhaled-corticosteroid-and-long-acting-beta2-agonist-therapy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-chf6001-dpi-with-roflumilast-for-patients-with-chronic-obstructive-pulmonary-disease-copd-and-chronic-bronchitis/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tanimilast-for-patients-with-chronic-obstructive-pulmonary-disease-copd-and-chronic-bronchitis/